In an unprecedented regulatory shift, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has announced plans to allow broader access to six previously restricted Peptides: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. This decision directly contradicts the advice of the Food and Drug Administration (FDA), which had not approved these substances following its rigorous evaluation process. The move follows a July vote by the Pharmacy Compounding Advisory Committee (PCAC) recommending that these compounds be moved to the 503A Bulks List, though the committee's recommendation was advisory and did not automatically grant approval.
The new "interim enforcement discretion policy" permits compounding pharmacies to prepare these six peptides without facing HHS enforcement action, provided they adhere to a strict set of conditions. According to Dustin Robinson, a lawyer at LumaLex Law, pharmacies are protected only if raw ingredients originate from FDA-registered manufacturers following good manufacturing practices and include a certificate of analysis verifying identity, purity, and the absence of contaminants like heavy metals. Furthermore, each product must contain only one peptide in specific forms, such as intranasal use for Semax, and cannot be sold over the counter; a prescription from a licensed physician is mandatory.
The HHS document explicitly cites Secretary Kennedy's advocacy for peptide use, stating that the policy aims to discourage the widespread use of research-only peptides supplied by foreign manufacturers while advancing patient choice. However, the FDA has not endorsed this decision. Reports indicate that while FDA staff helped draft safety guardrails, scientific staffers within the agency opposed the changes and had little input on the final decision. This lack of FDA approval means these peptides lack the safeguards associated with approved drugs, a concern highlighted by the 2025 death of Australian actor Richard Norton, which was linked to excess peptide use, though not one of the six in question.
Legal experts suggest this policy functions as a "highly specific safety valve" designed to rescue patients from a dangerous black market where peptides were previously sold under a "research purposes only" loophole. Jay Campbell, co-founder of the American Peptide Association, notes that the new rules require pharmacies to report serious adverse events and label products as compounded drugs not for resale. He argues this sets a quality standard for the industry, mandating specific testing before human use and potentially generating more real-world evidence through adverse event reporting.
Despite these regulatory steps, medical professionals emphasize that access should not be confused with scientific validation. Ava Shamban, MD, a board-certified dermatologist, warns that the policy creates a pathway for access but does not establish a new standard for FDA drug approval, which requires rigorous evaluation of safety, efficacy, and dosing. Steve Kates, PhD, from Dicerna Pharmaceuticals, adds that unlike approved drugs such as Ozempic, these peptides lack massive amounts of safety data derived from testing on thousands of people or statistically significant clinical trials.
The implementation of these rules is expected to impact the market significantly. Robinson notes that cutting out overseas supply chains may initially tighten manufacturing capacity and drive prices up. Campbell predicts a substantial price increase due to the costs of sourcing from FDA-registered manufacturers and conducting quality testing, which may not fully eliminate the gray market. Additionally, popular "stacks" of combined peptides are not covered under this declaration.
For consumers seeking these treatments, experts advise caution. Robinson recommends verifying that product labels state they are compounded drug products not for resale and asking pharmacies about ingredient manufacturing origins. Dr. Amanda Kahn, a board-certified internist, encourages patients to work with physicians who can assess risks and source compounds through reputable pharmacies rather than experimenting independently. While Koehl Robinson of CeliaRx views the move as validation for building infrastructure with physician oversight, she notes that her company's pharmacy is not set to open until 2027. Ultimately, legal experts reiterate that this policy does not change the legal status of the peptides or constitute a scientific finding that they are safe or effective.
Sources: Allure.